丰原药业
(000153)
| 流通市值：30.49亿 | | | 总市值：31.33亿 |
| 流通股本：4.52亿 | | | 总股本：4.65亿 |
| 报告期 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 2,027,143,954.81 | 940,757,024.36 | 4,284,620,583.14 | 3,261,422,843.25 |
| 营业收入 | 2,027,143,954.81 | 940,757,024.36 | 4,284,620,583.14 | 3,261,422,843.25 |
| 二、营业总成本 | 1,950,030,365.17 | 900,028,700.48 | 4,129,106,104.24 | 3,112,687,590.78 |
| 营业成本 | 1,626,812,677.72 | 734,073,801.33 | 3,352,142,795.05 | 2,525,865,523.95 |
| 税金及附加 | 16,844,249.25 | 7,883,763.79 | 33,962,006.19 | 26,103,971.1 |
| 销售费用 | 185,833,749.67 | 97,653,829.08 | 472,290,589.77 | 384,733,267.46 |
| 管理费用 | 74,273,275.39 | 35,681,496.94 | 178,623,419.99 | 114,105,171.23 |
| 研发费用 | 31,993,776.84 | 17,238,043.8 | 63,134,710.39 | 40,361,583.34 |
| 财务费用 | 14,272,636.3 | 7,497,765.54 | 28,952,582.85 | 21,518,073.7 |
| 其中:利息费用 | 16,153,107.49 | 8,336,459.95 | 30,361,057.66 | 23,037,925.31 |
| 其中:利息收入 | 2,038,890.31 | 981,353.78 | 2,184,232.81 | 1,904,128.83 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | -710,807.5 | -4,344,385.24 | -5,283,485.49 | -9,916,334.26 |
| 加:投资收益 | -600 | -600 | 9,220,093.88 | 9,902,752.75 |
| 资产处置收益 | - | - | -1,613,956.1 | -1,135,848.39 |
| 资产减值损失(新) | -2,904,926.49 | -1,462,911.9 | -5,177,068.1 | -1,279,211.87 |
| 信用减值损失(新) | -3,191,846.88 | -1,604,496.49 | -9,773,840.64 | -4,563,621.79 |
| 其他收益 | 18,369,506.53 | 10,544,434.21 | 62,199,931.31 | 41,454,662.17 |
| 四、营业利润 | 88,674,915.3 | 43,860,364.46 | 205,086,153.76 | 183,197,651.08 |
| 加:营业外收入 | 792,617.98 | 477,603.93 | 4,451,189.5 | 2,964,679.37 |
| 减:营业外支出 | 1,035,123.34 | 216,490.96 | 818,656.79 | 279,359.74 |
| 五、利润总额 | 88,432,409.94 | 44,121,477.43 | 208,718,686.47 | 185,882,970.71 |
| 减:所得税费用 | 13,430,009.53 | 6,793,777.44 | 51,067,779.73 | 40,791,878.17 |
| 六、净利润 | 75,002,400.41 | 37,327,699.99 | 157,650,906.74 | 145,091,092.54 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 75,002,400.41 | 37,327,699.99 | 157,650,906.74 | 145,091,092.54 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 76,278,476.53 | 38,020,772.3 | 160,834,825.11 | 147,302,850.89 |
| 少数股东损益 | -1,276,076.12 | -693,072.31 | -3,183,918.37 | -2,211,758.35 |
| 扣除非经常损益后的净利润 | 60,526,212.25 | 33,527,334.75 | 109,789,186.7 | 117,771,493.35 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 0.16 | 0.08 | 0.35 | 0.32 |
| (二)稀释每股收益 | 0.16 | 0.08 | 0.35 | 0.32 |
| 八、其他综合收益 | 42,553,953.6 | 5,223,904.42 | 5,136,856.98 | -808,596.84 |
| 归属于母公司股东的其他综合收益 | 42,429,670.82 | 5,168,521.94 | 4,966,506.25 | -963,258.21 |
| 九、综合收益总额 | 117,556,354.01 | 42,551,604.41 | 162,787,763.72 | 144,282,495.7 |
| 归属于母公司股东的综合收益总额 | 118,708,147.35 | 43,189,294.24 | 165,801,331.36 | 146,339,592.68 |
| 归属于少数股东的综合收益总额 | -1,151,793.34 | -637,689.83 | -3,013,567.64 | -2,057,096.98 |
| 公告日期 | 2025-08-22 | 2025-04-25 | 2025-04-11 | 2024-10-31 |
| 审计意见(境内) | | | 标准无保留意见 | |